Status:
COMPLETED
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
Millennium Pharmaceuticals, Inc.
Conditions:
Brain and Central Nervous System Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomid...
Detailed Description
OBJECTIVES: Primary * Estimate the overall survival at 2 years of patients with newly diagnosed glioblastoma multiforme treated with bortezomib in combination with temozolomide and regional radiothe...
Eligibility Criteria
Inclusion
- Must be \>- 18 years old, with a life expectancy \> 8 weeks
- Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma
- Must submit an unstained paraffin block or slides from surgical procedure
- Patients without prior treatment and with prior diagnosis of lower-grade gliomas that have been upgraded to GBM after repeated resection allowed
- At least 21 days since cranial MRI or contrast CT scan OR ≥ 96 hours since cranial MRI or contrast CT scan for patients who underwent surgical resection
- Measurable or assessable disease
- Voluntary written informed consent obtained before performance of any study related procedure not part of normal medical care.
- Karnofsky performance status \> 60%
- White Blood Count (WBC) ≥ 3,000/mm\^3
- absoulte neutrophil count(ANC) ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hemoglobin ≥ 10 g/dL (transfusion allowed)
- Bilirubin \< 2.5 times upper limit of normal (ULN)
- serum glutamic-oxaloacetic transaminase (SGOT) \< 2.5 times ULN
- Creatinine \< 1.5 mg/dL
- Creatinine clearance ≥ 20 mL/minute
- Serum sodium \> 130 mmol/L
- Negative pregnancy test
- Fertile patients must use effective contraception
- Patients on Enzyme-Inducing Antiepileptic Drugs (EIAED) must be transitioned to non- EAIED for ≥ 2 weeks
- Concurrent full-dose warfarin or its equivalent (e.g., unfractionated and/or low molecular weight heparin) allowed
Exclusion
- peripheral neuropathy ≥ grade 2
- Myocardial infarction within the past 6 months
- New York Heart Association (NYHA) class III or IV heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- hypersensitivity to bortezomib, boron, or mannitol
- serious medical or psychiatric illness that would interfere with study participation including, but not limited to, any of the following:
- Ongoing or active infection requiring IV antibiotics
- Psychiatric illness and/or social situations that would limit compliance with study requirements
- Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus)
- history of stroke within the past 6 months
- other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy
- significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
- disease that will obscure toxicity or dangerously alter drug metabolism
- viral hepatitis (HBV surface antigen positive) or active hepatitis C infection
- Prior or concurrent corticosteroids, automated external defibrillator, analgesics, and other drugs to treat symptoms or prevent complications allowed
- concurrent investigational drugs that must be stopped at least 4 months prior to therapy.
- prior radiotherapy to the brain
- prior cytotoxic or noncytotoxic drug therapy or experimental drug therapy (including chemotherapy, hormonal therapy, or immunotherapy) directed against the brain tumor
- prior polifeprosan 20 with carmustine implant (Gliadel wafer)
- concurrent stereotactic radiosurgery or brachytherapy
- concurrent sargramostim
- concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs \[EIAED\])
Key Trial Info
Start Date :
October 3 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00998010
Start Date
October 3 2011
End Date
April 20 2018
Last Update
August 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Los Angeles
Los Angeles, California, United States, 90095